Seizure
freedom with Keppra - a realistic goal
“A seizure reduction of 100% should be the primary measure of efficacy,
not only because of its impact on quality of life but because it is
the least subjective of measures”
(Krakow K, Walker M, Otoul C, et al. Neurology 2001;56:1772-1774. 1774 cols 1 and 2)
“Keppra has been investigated for 100% seizure
reduction over three years”
(Ben-Menachem E, Epileptic Disord 2003;5 (Suppl 1); S51-S55. S53 col
2 - mean duration of exposure, 1044.9 days - S54 col 2)
In the short-term
- Percentage of patients achieving seizure freedom in clinical audits
In the long-term
- Percentage of patients achieving 100% seizure reduction with
Keppra
“…LEV [Keppra] offers sustained efficacy in patients with refractory
partial seizures, and its
long-term tolerability is similar to that seen in the short-term
placebo-controlled trials.”
(Ben-Menachem E, Edrich P, Van Vleymen B, et al. Epilepsy Research
2003; 53: 57-64. 63 col 2, 64 col 1)
“These figures are significantly better than figures from other
continuation studies in which approximately 4% achieve seizure freedom
with the addition of a new antiepileptic drug [gabapentin, lamotrigine,
vigabatrin and topiramate].”
(Krakow K, Walker M, Otoul C, et al. Neurology 2001;56:1772-1774. 1774 col 2)
